The Latest Breaking News from FDA

The head of the Food and Drug Administration says a comprehensive review of the opioid painkillers that triggered the nation's ongoing overdose epidemic is in the works

Here's a roundup of top developments in the biotech space over the last 24 hours:

Leading healthcare company Abbott Laboratories (ABT) reported strong second-quarter results. And given the company is well-positioned to capitalize on its diverse business and recent FDA approvals, is it wise to buy the stock now? Let’s find out.

While humans evolved over a period of approximately 6 million years, breakthroughs in modern medicine as we know it today got going only in the 19th and 20th centuries. So how did humans successfully survive through millions of years of diseases and illnesses without modern drugs and treatments?

In 1984, President Ronald Reagan declared the third Sunday of each July to be “National Ice Cream Day,” and it doesn’t seem like a coincidence that he picked a date in the middle of the hottest month in the United States, climatologically speaking, to commemorate a treat enjoyed by more…

The Senate majority leader’s marijuana bill would pile on more taxes and regulations, despite years of complaints about the barriers they create.

As David Hodes first noted in The Green Market Report, the U.S. National Institutes of Health (NIH)’s growing interest in psychedel

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

The federal government has legalized cannabidiol (CBD). The FDA also has approved one cannabis-derived prescription drug, Epidiolex, for three rare seizure conditions.

Here's a roundup of top developments in the biotech space over the last 24 hours:

The Biden administration may scrap plans to expand eligibility for second boosters to younger adults. Instead, it's trying to speed up the next generation of boosters targeting the omicron variant.